Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Cancer Immunol Immunother. 2015 May 9;64(8):977–987. doi: 10.1007/s00262-015-1706-4

Fig. 3.

Fig. 3

CTL responses (ELISpot granzyme B secretion) were assessed Pre (week 0) and Post (week 6–9) treatment. Note the increase in CTL activity after immunizations of mCRC patients (P<0.05 Wilcoxon test). Values are Mean ± SEM.